How many insider trades does FilingIQ track for TARA?

FilingIQ tracks 218 Form 4 insider transactions for TARA (Protara Therapeutics, Inc.), covering filings from Jan 9, 2020 onwards. 2 of those were filed in the last 90 days.

Are TARA insiders net buyers or net sellers?

Across the full Form 4 history for TARA, 42 transactions (19%) were open-market purchases and 81 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TARA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TARA in?

Protara Therapeutics, Inc. (TARA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $276.37M.

TARA insider trading

NasdaqGM Healthcare

Protara Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

218

Last 90 days

Buys / sells

19% / 37%

Market cap

$276.37M

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Company website: www.protaratx.com

TARA insider activity at a glance

FilingIQ has scored 218 insider transactions for TARA since Jan 9, 2020. The most recent filing in our index is dated Apr 8, 2026.

Across the full history, 42 open-market purchases and 81 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TARA insider trades is 46.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TARA trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for TARA?: FilingIQ tracks 218 Form 4 insider transactions for TARA (Protara Therapeutics, Inc.), covering filings from Jan 9, 2020 onwards. 2 of those were filed in the last 90 days.
Are TARA insiders net buyers or net sellers?: Across the full Form 4 history for TARA, 42 transactions (19%) were open-market purchases and 81 (37%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TARA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TARA in?: Protara Therapeutics, Inc. (TARA) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $276.37M.

Methodology & sources

Every TARA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.